Table 5 Summary of the performances of K13 bMx prototype according to the origin of the samples (all samples, N = 590; samples collected from P. falciparum symptomatic patients, N = 544; and samples collected from the P. falciparum asymptomatic individuals, N = 46)

All samples

Sensitivity (CI 95%)

90.2%

(85.9–93.6)

95.8%

(88.1–99.1)

95.2%

(76.1–99.9)

90.0%

(68.3–98.8)

94.1%

(90.2–96.8)

Specificity (CI 95%)

99.4%

(97.6–99.9)

98.0%

(96.2–99.0)

100%

(99.4–100)

99.8%

(99.0–99.9)

92.4%

(89.2–94.9)

AUC

(CI 95%)

0.948

(0.927–0.965)

0.968

(0.951–0.981)

0.976

(0.961–0.987)

0.949

(0.928–0.965)

0.933

(0.909–0.952)

PPV

(CI 95%)

99.1%

(96.6–99.8)

86.1%

(77.5–91.7)

100%

94.7%

(71.6–99.2)

88.2%

(83.9–91.4)

NPV

(CI 95%)

93.0%

(90.1–95.1)

99.4%

(98.2–99.8)

99.8%

(98.9–99.9)

99.7%

(98.7–99.9)

96.3%

(93.9–97.8)

P. falciparum symptomatic patients

Sensitivity (CI 95%)

95.8%

(92.1–98.0)

95.8%

(88.1–99.1)

95.2%

(76.2–99.9)

90.0%

(68.3–98.8)

94.0%

(90.1–96.8)

Specificity (CI 95%)

99.4%

(97.8–99.9)

97.6%

(95.7–98.8)

100%

(99.3–100)

99.8%

(98.9–99.9)

96.0%

(93.3–97.9)

AUC

(CI 95%)

0.976

(0.958–0.987)

0.967

(0.949–0.981)

0.976

(0.960–0.987)

0.949

(0.927–0.966)

0.950

(0.929–0.967)

PPV

(CI 95%)

99.0%

(96.2–99.8)

86.1%

(77.5–91.7)

100%

94.7%

(71.6–99.2)

94.1%

(90.3–96.4)

NPV

(CI 95%)

97.3%

(95.1–98.6)

99.3%

(98.1–99.8)

99.8%

(98.7–99.9)

99.6%

(98.5–99.9)

96.0%

(93.4–97.6)

P. falciparum asymptomatic individuals

Sensitivity (CI 95%)

62.8%

(46.7–77.0)

100%

(29.2–100)

Specificity (CI 95%)

–

65.1%

(49.1–79.0)

AUC

(CI 95%)

0.314

(0.185–0.468)

0.826

(0.699–0.915)

PPV

(CI 95%)

90.0%

(87.7–91.9)

16.7%

(11.7–23.1)

NPV

(CI 95%)

–

100%